rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLCrsp-2046Research ArticleИНФОРМАЦИЯINFORMATIONXV Средиземноморский конгресс по ревматологии (Турция, Стамбул, 28–31 августа 2014 г.)15th MEDITERRANEAN RHEUMATOLOGY CONGRESS (ISTANBUL, TURKEY, 28–31 AUGUST 2014)СередавкинаН. В.SeredavkinaN. V.n_seredavkina@mail.ruДенисовЛ. Н.DenisovL. N.КоротаеваТ. В.KorotaevaT. V.КондратьеваЛ. В.KondratyevaL. V.ПодрядноваМ. В.PodryadnovaM. V.ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34АРоссияV.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522Russian Federation201512032015531101106Copyright © Середавкина Н.В., Денисов Л.Н., Коротаева Т.В., Кондратьева Л.В., Подряднова М.В., 20152015Середавкина Н.В., Денисов Л.Н., Коротаева Т.В., Кондратьева Л.В., Подряднова М.В.Seredavkina N.V., Denisov L.N., Korotaeva T.V., Kondratyeva L.V., Podryadnova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2046

В статье представлен краткий обзор материалов XV Средиземноморского конгресса по ревматологии, состоявшегося в августе 2014 г. в Стамбуле, Турция. Данный Конгресс объединяет ученых и врачей стран Средиземноморья и концентрирует интерес ревматологов и специалистов смежных специальностей на географических и этнографических особенностях структуры патологии населения, вызванной поражением опорно-двигательного аппарата воспалительного и метаболического генеза, своеобразии течения ревматических болезней и ответа на лечение. Целью Конгресса является не только представление информации по самым современным достижениям в ревматологии, но и создание условий для академического обмена знаниями на международном уровне и стимулирования новых исследований. 

The paper presents a brief review of the proceedings of the 15th Mediterranean Rheumatology Congress that was held in Istanbul, Turkey, in August 2014. This congress unites the scientists and physicians of Mediterranean countries and focuses the attention of rheumatologists and allied health professionals on the geographical and ethnical features of the pattern of human diseases caused by the inflammatory and metabolic involvement of the locomotor apparatus, as well as the peculiarity of the course of rheumatic diseases and treatment response. The goal of the congress is not only to present information on the latest advances in rheumatology, but also to create conditions for the academic exchange of knowledge at an international level and for the promotion of new investigations. 

V Средиземноморский конгресс по ревматологии15th Mediterranean Rheumatology CongressReferencesSimsek I, Yilmaz S, Sanal HT, et al. Protracted febrile myalgia of familial Mediterranean fever can be reliably detected by magnetic resonance imaging: a comprehensive analysis of 20 cases. Clin Exp Rheumatol. 2014;32(4 Suppl 83):S-6–7.Simsek I, Yilmaz S, Sanal HT, et al. Protracted febrile myalgia of familial Mediterranean fever can be reliably detected by magnetic resonance imaging: a comprehensive analysis of 20 cases. Clin Exp Rheumatol. 2014;32(4 Suppl 83):S-6–7.Kucuksahin O, Ilgen U, Ates A, et al. Anti-interleukin-1 treatment in 19 patients with familial Mediterranean fever. Clin Exp Rheumatol. 2014;32(4 Suppl 83):S-5.Kucuksahin O, Ilgen U, Ates A, et al. Anti-interleukin-1 treatment in 19 patients with familial Mediterranean fever. Clin Exp Rheumatol. 2014;32(4 Suppl 83):S-5.Estruch R. Mediterranean diet and disease. Proceedings of the 15th Mediterranean Congress of Rheumatology; 2014 August 28–31; Istanbul, Turkey.Estruch R. Mediterranean diet and disease. Proceedings of the 15th Mediterranean Congress of Rheumatology; 2014 August 28–31; Istanbul, Turkey.Salvarani C. PET. Proceedings of the 15th Mediterranean Congress of Rheumatology; 2014 August 28–31; Istanbul, Turkey.Salvarani C. PET. Proceedings of the 15th Mediterranean Congress of Rheumatology; 2014 August 28–31; Istanbul, Turkey.Pipitone N, Versari A, Salvarani C. Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. Rheumatology (Oxford). 2008;47(4):403–8. DOI: 10.1093/rheumatology/kem379. Epub 2008 Feb 21.Pipitone N, Versari A, Salvarani C. Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. Rheumatology (Oxford). 2008;47(4):403–8. DOI: 10.1093/rheumatology/kem379. Epub 2008 Feb 21.Ghinoi A, Pipitone N, Nicolini A, et al. Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. Rheumatology (Oxford). 2012 Apr;51(4):730–4. DOI: 10.1093/rheumatology/ker329. Epub 2011 Dec 16.Ghinoi A, Pipitone N, Nicolini A, et al. Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. Rheumatology (Oxford). 2012 Apr;51(4):730–4. DOI: 10.1093/rheumatology/ker329. Epub 2011 Dec 16.Schmidt WA, Seifert A, Gromnica-Ihle E, et al. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford). 2008;47(1):96–101. DOI: 10.1093/rheumatology/kem322Schmidt WA, Seifert A, Gromnica-Ihle E, et al. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford). 2008;47(1):96–101. DOI: 10.1093/rheumatology/kem322Agard C, Barrier JH, Dupas B, et al. Aortic involvement in recentonset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan. Arthritis Rheum. 2008 May 15;59(5):670–6. DOI: 10.1002/art.23577.Agard C, Barrier JH, Dupas B, et al. Aortic involvement in recentonset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan. Arthritis Rheum. 2008 May 15;59(5):670–6. DOI: 10.1002/art.23577.Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55(1):131–7. DOI: 10.1002/art.21699Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55(1):131–7. DOI: 10.1002/art.21699Meller J, Strutz F, Siefker U, et al. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging. 2003;30(5):730–6. DOI: 10.1007/s00259-003-1144-y. Epub 2003 Apr 4.Meller J, Strutz F, Siefker U, et al. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging. 2003;30(5):730–6. DOI: 10.1007/s00259-003-1144-y. Epub 2003 Apr 4.Kaplan MJ. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol. 2006;18(3):289–97. DOI: 10.1097/01.bor.0000218951.65601.bfKaplan MJ. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol. 2006;18(3):289–97. DOI: 10.1097/01.bor.0000218951.65601.bfOstojic P, Bartolovic D, Cvijovic A, et al. Impact of disease activity, obesity and depression on lipid status, glycoregulation and risk for coronary heart disease in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2014;32(4 Suppl 83):S-3.Ostojic P, Bartolovic D, Cvijovic A, et al. Impact of disease activity, obesity and depression on lipid status, glycoregulation and risk for coronary heart disease in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2014;32(4 Suppl 83):S-3.Garip Y, Eser F, Bodur H. Prevalence of comorbidities in Turkish patients with ankylosing spondilities: impact on the health-related quality of life in turms of disease activity, functional status, severity of pain and social and emotional functioning. Clin Exp Rheumatol. 2014;32(4 Suppl 83):S-60.Garip Y, Eser F, Bodur H. Prevalence of comorbidities in Turkish patients with ankylosing spondilities: impact on the health-related quality of life in turms of disease activity, functional status, severity of pain and social and emotional functioning. Clin Exp Rheumatol. 2014;32(4 Suppl 83):S-60.Smolen JS, Landew? R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–75. DOI: 10.1136/ard.2009.126532. Epub 2010 May 5.Smolen JS, Landew? R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–75. DOI: 10.1136/ard.2009.126532. Epub 2010 May 5.Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173:837–46. DOI: 10.1111/j.1749-6632.2009.04621.x.Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173:837–46. DOI: 10.1111/j.1749-6632.2009.04621.x.Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 2007;66(7):893–9. DOI: 10.1136/ard.2006.068304. Epub 2007 Apr 5.Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 2007;66(7):893–9. DOI: 10.1136/ard.2006.068304. Epub 2007 Apr 5.Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210–21. DOI: 10.1016/S0140-6736(09)60506-7. Epub 2009 Jun 26.Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210–21. DOI: 10.1016/S0140-6736(09)60506-7. Epub 2009 Jun 26.Caporali R, Sarzi-Puttini P, Atzeni F, et al. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev. 2010;9(6):465–9. DOI: 10.1016/j.autrev.2009.12.010. Epub 2009 Dec 31.Caporali R, Sarzi-Puttini P, Atzeni F, et al. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev. 2010;9(6):465–9. DOI: 10.1016/j.autrev.2009.12.010. Epub 2009 Dec 31.Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebocontrolled trial. Ann Rheum Dis. 2008;67(11):1516–23. DOI: 10.1136/ard.2008.092932. Epub 2008 Jul 14.Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebocontrolled trial. Ann Rheum Dis. 2008;67(11):1516–23. DOI: 10.1136/ard.2008.092932. Epub 2008 Jul 14.Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005 Sep 15;353(11):1114–23. DOI: 10.1056/NEJMoa050524Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005 Sep 15;353(11):1114–23. DOI: 10.1056/NEJMoa050524Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–806. DOI: 10.1002/art.22025Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–806. DOI: 10.1002/art.22025Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis. 2012;71(8):1303–8. DOI: 10.1136/annrheumdis-2011-200490. Epub 2012 Jan 30.Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis. 2012;71(8):1303–8. DOI: 10.1136/annrheumdis-2011-200490. Epub 2012 Jan 30.Gomez-Reino JJ, Maneiro JR, Ruiz J, et al. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis. 2012;71(11):1861–4. DOI: 10.1136/annrheumdis-2012-201324. Epub 2012 Jun 26.Gomez-Reino JJ, Maneiro JR, Ruiz J, et al. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis. 2012;71(11):1861–4. DOI: 10.1136/annrheumdis-2012-201324. Epub 2012 Jun 26.Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56(5):1417–23. DOI: 10.1002/art.22520Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56(5):1417–23. DOI: 10.1002/art.22520Soliman MM, Hyrich KL, Lunt M, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2012;64(8):1108–15. DOI: 10.1002/acr.21663.Soliman MM, Hyrich KL, Lunt M, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2012;64(8):1108–15. DOI: 10.1002/acr.21663.Yoshida K, Tokuda Y, Oshikawa H, et al. An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology (Oxford). 2011;50(11):2093–9. DOI: 10.1093/rheumatology/ker295. Epub 2011 Sep 2.Yoshida K, Tokuda Y, Oshikawa H, et al. An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology (Oxford). 2011;50(11):2093–9. DOI: 10.1093/rheumatology/ker295. Epub 2011 Sep 2.Favalli EG, Biggioggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014;53(9):1664–8. DOI: 10.1093/rheumatology/keu158. Epub 2014 Apr 12.Favalli EG, Biggioggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014;53(9):1664–8. DOI: 10.1093/rheumatology/keu158. Epub 2014 Apr 12.Parisi S, Fusaro E, Lumetti F, et al. Survival on treatment with second-third biologic therapy: switching vs swapping. Clin Exp Rheumatol. 2014;32(4 Suppl 83):S-3–4.Parisi S, Fusaro E, Lumetti F, et al. Survival on treatment with second-third biologic therapy: switching vs swapping. Clin Exp Rheumatol. 2014;32(4 Suppl 83):S-3–4.Sidiropolos P, Flouri I. Hellenic Registry for biologic therapies. Clin Exp Rheumatol. 2014;32(4 Suppl 83):S-5.Sidiropolos P, Flouri I. Hellenic Registry for biologic therapies. Clin Exp Rheumatol. 2014;32(4 Suppl 83):S-5.Flouri I, Markatseli TE, Voulgari PV, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014;43(4):447–57. DOI: 10.1016/j.semarthrit.2013.07.011. Epub 2013 Sep 6.Flouri I, Markatseli TE, Voulgari PV, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014;43(4):447–57. DOI: 10.1016/j.semarthrit.2013.07.011. Epub 2013 Sep 6.Mola EM. Future prospects for biosimilars in Mediterranean. Proceedings of the 15th Mediterranean Congress of Rheumatology; 2014 August 28–31; Istanbul, Turkey.Mola EM. Future prospects for biosimilars in Mediterranean. Proceedings of the 15th Mediterranean Congress of Rheumatology; 2014 August 28–31; Istanbul, Turkey.

The authors declare that there are no conflicts of interest present.